AZNCF News and Press, AstraZeneca Plc

2024-07-29 15:45:45 ET Summary Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size is estimated to reach $2.2 billion by 2028; Up to ...

2024-07-29 12:19:39 ET Summary On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the three months ended June 30, 2024, an increase of 55.8...

2024-07-28 01:24:46 ET Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, an...

2024-07-25 12:25:12 ET AstraZeneca PLC (AZN) Q2 2024 Earnings Conference Call July 25, 2024, 06:45 ET Company Participants Andy Barnett - Head, IR Pascal Soriot - Executive Director & CEO Aradhana Sarin - Executive Director & CFO David Fredrickson - E...

2024-07-25 02:07:51 ET More on AstraZeneca AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings AstraZeneca's Oncology Success: Fueling Future Growth AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) Here are Big Pha...

2024-07-24 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global equities rose i...

2024-07-19 06:50:00 ET Summary Parnassus Growth Equity Fund (Investor Shares) returned 3.74% (net of fees) for the quarter, underperforming the Russell 1000 Growth Index’s 8.33%. The underperformance was primarily driven by our stock selection in the Information Technology ...

2024-07-18 13:50:41 ET Summary AstraZeneca PLC will announce its Q2 earnings next Thursday, 25th July. In Q1, the company showed 19% year-on-year revenue growth and 13% EPS growth. Guidance for 2024 is for double-digit growth at the top and bottom lines — it's possible ...

2024-07-18 13:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International equities...

2024-07-17 04:42:00 ET Summary As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors. ...